Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed that it repurchased 53,000 H shares on 6 October 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed within a price range of HKD 21.38–21.88 per share, representing a total cash outlay of approximately HKD 1.15 million.

Following the transaction, the company’s issued share count (excluding treasury shares) fell by 0.016 % to 322.06 million shares, while treasury shares rose to 14.29 million. Total issued shares remained unchanged at 336.35 million.

The purchase forms part of a broader mandate approved on 13 May 2026 that authorises Zylox-Tonbridge to buy back up to 32.72 million shares. Cumulative repurchases under this mandate now stand at 5.39 million shares, equal to 1.61 % of the issued share base at the time the authority was granted.

In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 5 November 2026.